Liftstream is an executive search recruitment company in the life sciences sector
Prosensa begins FDA submission process for DMD drug
Authored by James Sheppard
Prosensa announces senior management and board appointments
Authored by Karl Simpson
Posted in Executive Appointments, Orphan Drugs and Rare Diseases, Recruitment Market
Tagged Annalisa jenkins, Board of Directors, Chief Commerical Officer, DMD, Duchenne Muscular Dytrophy, Genzyme, GSK, Merck Serono, Prosensa, R&D, research and development, to-BBB, Willem W. van Weperen
Leave a comment
Rare Disease Biotech Summit plc Appoints Erik Ostrowski as CFO
Authored by James Sheppard
PTC Therapeutics appoints Chief Medical Officer and communicates CHMP conditional decision
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Ariad, Ataluren, Chief Medical Officer, CHMP, DMD, Duchenne, Duchenne Muscular Dystrophy, EMA, europe, GSK, Iclusig, investors, MAA, market authorisation application, Murad Husain, oncology, parents, patients, phase III clinical trial, Prosensa, PTC Therapeutics, Rober J. Spiegel, Sarepta, USA, VP Global Regulatory Affairs
Leave a comment
Prosensa, Sarepta, PTC, Summit and DART all contribute to the ubiquity of news in Duchenne
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Amsterdam Biotech, Ataluren, Charity, clinical, DART Therapeutics, DMD, Drisapersen, Duchenne Muscular Dystrophy, Eteplirsen, FDA, Gene Williams, Glynn Edwards, GSK, GSK/Prosensa, HT-100, IPO, Market Access, NASDAQ, Netherlands, Orphan drugs, Oxford Biotech, phase II studies, Priority Review, Prosensa, PTC Therapeutics, Rare Disease, regulatory affairs, research and development, Sarepta Therapeutics, Save our Sons, SMT C1100, Summit plc, UK, USA, Utrophin, utrophin modulation
2 Comments
Biotech IPO fever spreads from West to East
Authored by Karl Simpson
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Ataluren, Biopolis, cardiomyocytes, derived neurons, DMD, Duchenne Muscular Dystrophy, Human iPSC, Institute of Medical Sciences, IPO, Japan, JASDAQ, Kyoto University, Malaysia Biotech, New Zealand Biotech, Prof. Hiromitsu Nakauchi, Prof. Norio Nakatsuji, PTC Therapeutics, ReproCELL, Stem Cell, University of Tokyo
Leave a comment
Kurma Life Science Partners Launches new Biotech Fund for Rare Diseases
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Avalon Ventures, BLiNK, CDC Enterprise, DMD, Duchenne Muscular Dystrophy, European Research Institutes, France, GSK, Idinvest Partners, KLS Partners, Kurma, Kurma Biofund, Kurma Life Science Partners, NEA, New Enterprise Associates, oncology, Orphan drugs, partnering, Prosensa, rare diseases, VC, venture capital
Leave a comment
Santhera seeks US partner for DMD program
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Catena, DELPHI, DMD, Duchenne, Duchenne Muscular Dystrophy, EMA, FDA, Santhera, Switzerland, Thomas Meier
Leave a comment
David Motts’ NEA weighs in on rare diseases
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged AstraZeneca, Cambridge MA, Clarus Ventures, Cydan, David Mott, DMD, Dr. Cristina Csimma, Duchenne Muscular Dystrophy, GSK, International Rare Diseases Research Consortium, James McArthur, MedImmune, NEA, Orphan Drug, orphan drug accelerator, Prosensa, Rare Disease, Treat-NMD, Virdante Pharmaceuticals, Wyeth
Leave a comment